论文部分内容阅读
目的：观察促性腺激素释放激素（ＬＨＲＨ）高效类似物那法瑞林对人乳腺癌ＢＣａＰ－３７细胞裸鼠移植瘤生长的抑制作用并探讨其作用机制。方法：那法瑞林用药分为移植瘤接种后次日给药组及接种后２周给药组，每组各设３个剂量，均连续皮下给药４周。使用他莫昔芬和另一ＬＨＲＨ激动剂Ｄ－Ｔｒｐ６ＬＨＲＨ作为阳性对照。用药结束后，分别测定移植瘤、双侧卵巢、子宫质量和血清雌二醇（Ｅ２）含量；进行病理检查（包括电镜）；测定移植瘤细胞ＤＮＡ指数（ＤＩ）；观察瘤细胞增殖周期比例的变化。结果：（１）在以上不同的两用药组中，那法瑞林剂量在５００和１０００μｇ／ｋｇ时，可以显著抑制移植瘤的生长，移植瘤的ＤＩ值明显下降，通过电镜观察到瘤组织内存在凋亡的瘤细胞。同时，动物的卵巢质量和血清Ｅ２含量显著下降。（２）他莫昔芬３０ｍｇ／ｋｇ对移植瘤生长无显著影响，与Ｄ－Ｔｒｐ６ＬＨＲＨ抑制移植瘤生长的作用相比亦无显著差别。结论：那法瑞林长期皮下给药对ＢＣａＰ－３７移植瘤生长有显著的抑制作用。
OBJECTIVE: To investigate the inhibitory effect of gonadotropin-releasing hormone (LHRH) high-efficiency analogue nafarelin on the growth of human breast cancer BCaP-37 xenografts in nude mice and to explore its mechanism of action. METHODS: Nafarilin was divided into two groups: the next day after the inoculation of the transplanted tumors and the two weeks after the inoculation. Three doses were used in each group, and all were administered subcutaneously for 4 weeks. Tamoxifen and another LHRH agonist D-Trp6LHRH were used as positive controls. At the end of treatment, the tumors, bilateral ovaries, uterus mass and serum estradiol (E2) content were measured. Pathological examination (including electron microscopy) was performed; the DNA index (DI) of the transplanted tumor cells was measured; and the proportion of tumor cell proliferation cycle was observed. Variety. RESULTS: (1) In the above two different drug groups, nafarelin doses of 500 and 1000 μg/kg significantly inhibited the growth of the transplanted tumors. The DI value of the transplanted tumors was significantly decreased, and the tumor tissue was observed by electron microscopy. In apoptotic tumor cells. At the same time, the animal’s ovarian mass and serum E2 content decreased significantly. (2) Tamoxifen 30 mg/kg had no significant effect on the growth of transplanted tumors, and there was no significant difference compared with the effect of D-Trp6LHRH on inhibiting the growth of transplanted tumors. CONCLUSION: Long-term subcutaneous administration of nafarelin significantly inhibits the growth of BCaP-37 transplanted tumors.